translation agency

NLM AIDSLINE
Use of letrazuril in refractory cryptosporidiosis in AIDS.
Walach C; Loeb M; Phillips J; Salit I; Rachlis A; Fong I; Walmsley S;
November 30, 1993
Int Conf AIDS. 1993 Jun 6-11;9(1):380 (abstract no. PO-B10-1472). Unique

OBJECTIVE: To determine the clinical and microbiologic effectiveness of Letrazuril in cryptosporidiosis in AIDS. METHODS: 24 HIV-positive patients (average CD4 count = 37.5 x 10(6)/L) with cryptosporidiosis were treated with Letrazuril 50 mg/day. All pts had previously been treated with paramomycin for an average of 3.2 months and had either failed (23 pt) or suffered an adverse event (1 pt) from that agent. RESULTS: At the initiation of Letrazuril, 25% had mild (2-4 bowel movements BM)/day), 42% moderate (5-9 BM/day) and 33% severe diarrhea (> 10 BM/day) and in 87.5% the diarrhea was liquid in consistency. 4% of pts had a complete and 50% had a partial clinical response. Microbiologic eradication of the organism was demonstrated in 44% of evaluable pts. 50% of responding pts experienced a clinical relapse an average of 1.6 mos following the initiation of Letrazuril. The other 50% of responders have symptom control at an average of 3.1 mon after the initiation of Letrazuril. Four pts required drug discontinuation due to rash. 50% of the pts required rehydration with IV fluids and 20% received TPN. 67% pts remain alive an average of 6.1 mos after diagnosis of cryptosporidiosis, 33% pts died an average of 3.0 mos after their diagnosis and in 87.5% cryptosporidium significantly contributed to death. CONCLUSIONS: Patients with refractory cryptosporidiosis may respond to Letrazuril, however, response is incomplete and transient. Letrazuril requires further evaluation, particularly earlier in cryptosporidiosis.

*Acetonitriles/THERAPEUTIC USE *AIDS-Related Opportunistic Infections/DRUG THERAPY *Coccidiostats/THERAPEUTIC USE *Cryptosporidiosis/DRUG THERAPY *HIV Seropositivity/COMPLICATIONS *Triazines/THERAPEUTIC USE

www.aegis.org